Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.56 |
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649049 | 0.87 | KDM4E (0.72) | KDM4ETDP1POLBNPC1MAPK1 | |
| SCHEMBL9973847 | 0.86 | HCAR2 (0.67) | KDM4EPOLBNPC1MAPK1HCAR2 | |
| SCHEMBL15647380 | 0.86 | KMT2A (0.67) | KDM4ETDP1POLBMAPK1MEN1 | |
| SCHEMBL27521280 | 0.84 | HCAR2 (0.73) | KDM4EHCAR2 | |
| SCHEMBL16653886 | 0.84 | KDM4E (0.57) | KDM4ETDP1POLBNPC1MAPK1 | |
| SCHEMBL27546619 | 0.84 | HCAR2 (0.64) | KDM4EHCAR2 | |
| SCHEMBL27546742 | 0.83 | ALOX15 (0.69) | KDM4EPOLBMAPK1MEN1KMT2A | |
| SCHEMBL20472023 | 0.83 | NPC1 (0.61) | KDM4EPOLBNPC1MAPK1MEN1 | |
| SCHEMBL10497116 | 0.82 | HCAR2 (0.78) | KDM4ENPC1HCAR2KDM6BKDM4D | |
| SCHEMBL29170998 | 0.81 | NPC1 (0.58) | KDM4EPOLBNPC1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802064-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2416660-B1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20130345173-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8546564-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC. | 2012-04-19 | — | — | US | disclosed |
| EP-2416660-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118155-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345173-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, FFAR3 | KDM4E 2972/4885TDP1 2761/4885POLB 4210/4885 |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, FFAR3 | KDM4E 2774/4885TDP1 2900/4885POLB 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.